Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Respondents reported on their feelings about antiretrovirals, their relationships with their clinicians and dealing with stigma.
A recent small study compared objective and subjective fatigue among those with and without HIV who were age 50 and older.
Scientists reached this finding thanks to a highly precise means of sequencing HIV’s genetics.
Livers from those who test positive for hep C antibodies but negative for viral genes are tied to only a modest transmission risk.
A CDC testing program also revealed many disparities in linkage to care for the virus.
This is according to a recent survey of gay and bi men taking daily Truvada as PrEP.
Researchers identified this advancing risk after controlling for expected cognitive decline based on age.
This finding applies to those with Child-Pugh A cirrhosis who are treated with the Viekira regimen or Technivie, with or without ribavirin.
This finding falls in line with numerous analyses that show that PrEP’s benefits are largely not reaching Black gay and bi men.
Gilead Sciences’ second round of cure grants supports these five research projects.
Compared with the older tenofovir, called TDF, the new one, TAF, suppressed the virus as well and offered bone, kidney and lipid benefits.
However, there is still room for improvement in ensuring a largely indigent population of people with HIV gets access to medical care.
Results from a Phase III trial showed Symtuza worked as well as a boosted protease inhibitor–based antiretroviral regimen.
More research is needed to determine the metabolic implications of this apparent association and how it may drive diabetes.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.